Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer

NCT ID: NCT02453009

Last Updated: 2024-05-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 246 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-10-31
• Study Completion Date: 2019-04-30

Brief Summary

The aim of this study is to verify if the addition of enzalutamide to docetaxel is able to improve the disease control in first line CRPC patients.

Detailed Description

CHEIRON trial is a phase II randomized study comparing docetaxel plus enzalutamide to docetaxel alone as first line for castration resistant prostate cancer.

Conditions

Prostatic Neoplasms

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm A

Docetaxel 75 mg/m² intravenously on day 1 every 3 weeks for 8 cycles, plus oral prednisone 10 mg daily for 24 weeks plus oral enzalutamide 160 mg daily for 24 weeks

Group Type: EXPERIMENTAL

Docetaxel

Intervention Type: DRUG

Pharmaceutical form:solution Route of administration: intravenous

Prednisone

Intervention Type: DRUG

Pharmaceutical form:tablet Route of administration: oral

Enzalutamide

Intervention Type: DRUG

Pharmaceutical form : soft gelatin capsules Route of administration: oral

Arm B

Docetaxel 75 mg/m² intravenously on day 1 every 3 weeks for 8 cycles, plus oral prednisone 10 mg daily for 24 weeks

Group Type: ACTIVE_COMPARATOR

Docetaxel

Intervention Type: DRUG

Pharmaceutical form:solution Route of administration: intravenous

Prednisone

Intervention Type: DRUG

Pharmaceutical form:tablet Route of administration: oral

Interventions

Docetaxel

Pharmaceutical form:solution Route of administration: intravenous

Intervention Type: DRUG

Prednisone

Pharmaceutical form:tablet Route of administration: oral

Intervention Type: DRUG

Enzalutamide

Pharmaceutical form : soft gelatin capsules Route of administration: oral

Intervention Type: DRUG

Other Intervention Names

Xtandi

Eligibility Criteria

Inclusion Criteria

1. Histologically- or cytologically-confirmed prostate adenocarcinoma.

2. Metastatic disease.

3. Progressive disease while receiving hormonal therapy or after surgical castration documented by at least one of the following:

• Increase in measurable disease (RECIST 1.1) [15], and/or
• Appearance of new lesions, including those on bone scan consistent with progressive prostate cancer, and/or
• Rising PSA defined as 2 sequential increases above a previous lowest reference value. Each value must be obtained at least 1 week apart. A PSA value of at least 2 ng/ml is required at study entry.
• Effective castration (serum testosterone levels ≤0.50 ng/dL) by orchiectomy and/or LHRH agonists or antagonist with or without anti-androgens.

i. If the patient has been treated with LHRH agonists or antagonist (i.e., without orchiectomy), then this therapy should be continued.

ii. If patients were either started on complete androgen blockade, or had a PSA response (defined by any reduction in PSA sustained for at least 3 months) after adding an antiandrogen, prior anti-androgen therapy should be stopped before randomization: at least 6 weeks for bicalutamide and nilutamide, and at least 4 weeks for flutamide, megestrol acetate and any other hormonal therapy.

4. More than 18 years.

5. Eastern Cooperative Oncology Group (ECOG) performance status <2 (see Appendix 2).

6. Ability to fill the quality of life questionnaire

7. Patient compliance and geographic proximity that allow adequate follow-up.

8. Presence of signed and dated IRB-approved patient informed consent form prior to enrollment into the study.

Exclusion Criteria

1. Prior chemotherapy for prostate cancer, except estramustine and except adjuvant/neoadjuvant treatment completed >3 years ago.

2. Prior treatment with abiraterone acetate and/or enzalutamide

3. Less than 28 days elapsed from prior treatment with estramustine, radiotherapy or surgery to the time of randomization. Patients may be on biphosphonates prior to study entry.

4. Prior isotope therapy, whole pelvic radiotherapy, or radiotherapy to >30% of bone marrow.

5. History of brain metastases, uncontrolled spinal cord compression, or carcinomatous meningitis or new evidence of brain or leptomeningeal disease.

6. History of seizure or any condition that may predispose to seizure (eg, prior cortical stroke or significant brain trauma). History of loss of consciousness or transient ischemic attack within 12 months of randomization;

7. Inadequate organ and bone marrow function

8. Contraindications to the use of corticosteroid treatment.

9. Clinically significant cardiovascular disease

10. Any of the following within 3 months prior to randomization: treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism, or other uncontrolled thromboembolic event.

11. Hypersensitivity reaction to the active pharmaceutical ingredient or any of the capsule components, including Labrasol, butylated hydroxyanisole, and butylated hydroxytoluene;

12. Prior malignancy. Adequately treated basal cell or squamous cell skin or superficial (pTis, pTa, and pT1) bladder cancer are allowed, as well as any other cancer for which chemotherapy has been completed >5 years ago and from which the patient has been disease-free for >5 years.

13. Participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to randomization.

14. Any other condition which in the judgment of the investigator would place the subject at undue risk or interfere with the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Santa Chiara Hospital

OTHER

Sponsor Role: lead

Responsible Party

Orazio Caffo

MD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Orazio Caffo, MD

Role: STUDY_CHAIR

Santa Chiara Hospital

Locations

Santa Chiara Hospital

Trento, , Italy

Countries

Italy

References

Caffo O, Ortega C, Nole F, Gasparro D, Mucciarini C, Aieta M, Zagonel V, Iacovelli R, De Giorgi U, Facchini G, Veccia A, Palesandro E, Verri E, Buti S, Razzini G, Bozza G, Maruzzo M, Ciccarese C, Schepisi G, Rossetti S, Maines F, Kinspergher S, Fratino L, Ermacora P, Nicodemo M, Giordano M, Sartori D, Scapoli D, Sabbatini R, Lo Re G, Morelli F, D'Angelo A, Vittimberga I, Lippe P, Carrozza F, Messina C, Galli L, Valcamonico F, Porta C, Pappagallo G, Aglietta M. Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. Eur J Cancer. 2021 Sep;155:56-63. doi: 10.1016/j.ejca.2021.06.016. Epub 2021 Aug 3.

Reference Type: DERIVED

PMID: 34358777 (View on PubMed)

Other Identifiers

TN-CHEIRON

Identifier Type: -

Identifier Source: org_study_id